TriSalus Life Sciences (TLSI) Cash & Equivalents (2021 - 2026)

TriSalus Life Sciences (TLSI) has 6 years of Cash & Equivalents data on file, last reported at $56.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 335.02% year-over-year to $56.6 million; the trailing twelve-month figure through Mar 2026 stood at $56.6 million (up 335.02% YoY), and the FY2025 full-year result was $20.4 million, up 139.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $56.6 million, up from $20.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $56.6 million in Q1 2026 and bottomed at $69182.0 in Q2 2022.
• The 5-year median for Cash & Equivalents is $11.5 million (2023), against an average of $13.9 million.
• Peak annual rise in Cash & Equivalents reached 15750.93% in 2024, while the deepest fall reached 47.21% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $9.4 million in 2022, then rose by 25.1% to $11.8 million in 2023, then decreased by 27.61% to $8.5 million in 2024, then soared by 139.75% to $20.4 million in 2025, then soared by 176.69% to $56.6 million in 2026.
• The last three Cash & Equivalents figures came in at $56.6 million (Q1 2026), $20.4 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.

Peer Comparison